Convalescent Plasma for the Treatment of Severe COVID-19

Massimo Franchini, Giancarlo Maria Liumbruno Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, ItalyCorrespondence: Massimo FranchiniDepartment of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, ItalyTel +039-0376-201234Fax +039-0376-220144Email mass...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Franchini M, Liumbruno GM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	sars-cov-2 covid-19 hyperimmune plasma convalescent plasma therapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/3f144f633a8249edb3bfb220096af548
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3f144f633a8249edb3bfb220096af548
record_format	dspace
spelling	oai:doaj.org-article:3f144f633a8249edb3bfb220096af5482021-12-02T14:24:11ZConvalescent Plasma for the Treatment of Severe COVID-191177-5491https://doaj.org/article/3f144f633a8249edb3bfb220096af5482021-02-01T00:00:00Zhttps://www.dovepress.com/convalescent-plasma-for-the-treatment-of-severe-covid-19-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Massimo Franchini, Giancarlo Maria Liumbruno Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, ItalyCorrespondence: Massimo FranchiniDepartment of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, ItalyTel +039-0376-201234Fax +039-0376-220144Email massimo.franchini@asst-mantova.itAbstract: The COVID-19 pandemic in 2020 is one of the worst catastrophic events in human history. Several non-specific antiviral drugs have been tried to defeat the SARS-CoV-2, with mixed results. Convalescent plasma from patients who have recovered from COVID-19 is one of the specific biologic therapies being considered to treat SARS-CoV-2 infection. Preliminary studies have shown that convalescent plasma, containing antibodies able to neutralize SARS-CoV-2, is promising in blocking viral replication and improving patients’ clinical symptoms. The results of several ongoing randomized controlled trials are, however, keenly awaited to definitively elucidate the safety and efficacy of this blood component in COVID-19. In this narrative review, we summarize the current evidence from the literature on the treatment of severe COVID-19 with convalescent plasma. A concise overview of the hypothesized mechanisms of action is also presented.Keywords: SARS-CoV-2, COVID-19, hyperimmune plasma, convalescent plasma, therapyFranchini MLiumbruno GMDove Medical Pressarticlesars-cov-2covid-19hyperimmune plasmaconvalescent plasmatherapyMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 15, Pp 31-38 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	sars-cov-2 covid-19 hyperimmune plasma convalescent plasma therapy Medicine (General) R5-920
spellingShingle	sars-cov-2 covid-19 hyperimmune plasma convalescent plasma therapy Medicine (General) R5-920 Franchini M Liumbruno GM Convalescent Plasma for the Treatment of Severe COVID-19
description	Massimo Franchini, Giancarlo Maria Liumbruno Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, ItalyCorrespondence: Massimo FranchiniDepartment of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, ItalyTel +039-0376-201234Fax +039-0376-220144Email massimo.franchini@asst-mantova.itAbstract: The COVID-19 pandemic in 2020 is one of the worst catastrophic events in human history. Several non-specific antiviral drugs have been tried to defeat the SARS-CoV-2, with mixed results. Convalescent plasma from patients who have recovered from COVID-19 is one of the specific biologic therapies being considered to treat SARS-CoV-2 infection. Preliminary studies have shown that convalescent plasma, containing antibodies able to neutralize SARS-CoV-2, is promising in blocking viral replication and improving patients’ clinical symptoms. The results of several ongoing randomized controlled trials are, however, keenly awaited to definitively elucidate the safety and efficacy of this blood component in COVID-19. In this narrative review, we summarize the current evidence from the literature on the treatment of severe COVID-19 with convalescent plasma. A concise overview of the hypothesized mechanisms of action is also presented.Keywords: SARS-CoV-2, COVID-19, hyperimmune plasma, convalescent plasma, therapy
format	article
author	Franchini M Liumbruno GM
author_facet	Franchini M Liumbruno GM
author_sort	Franchini M
title	Convalescent Plasma for the Treatment of Severe COVID-19
title_short	Convalescent Plasma for the Treatment of Severe COVID-19
title_full	Convalescent Plasma for the Treatment of Severe COVID-19
title_fullStr	Convalescent Plasma for the Treatment of Severe COVID-19
title_full_unstemmed	Convalescent Plasma for the Treatment of Severe COVID-19
title_sort	convalescent plasma for the treatment of severe covid-19
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/3f144f633a8249edb3bfb220096af548
work_keys_str_mv	AT franchinim convalescentplasmaforthetreatmentofseverecovid19 AT liumbrunogm convalescentplasmaforthetreatmentofseverecovid19
_version_	1718391422132944896

Convalescent Plasma for the Treatment of Severe COVID-19

Ejemplares similares